Tabell
Hovedbudskap |
|
- 1.
Nymdelger S, Nieber K. Pregabalin: a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and fibromyalgia syndrome. Med Monatsschr Pharm 2007; 30: 396 – 400.
- 2.
Forseth K, Gran J. Fibromyalgi og medikamentell behandling Tidsskr Nor Lægeforen 2006; 126: 1486 – 7.
- 3.
Folkehelseinstituttet. Reseptregisteret. Legemiddelforbruket i Norge 2000. www.legemiddelforbruket.no (13.3.2008).
- 4.
Hallas J, Støvring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol 2006; 98: 260 – 5.
- 5.
Bramness JG, Furu K, Engeland A et al. Carisoprodol use and abuse in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 2007; 64: 210 – 8.
- 6.
Henriksen J. Smertepasienter hamstrer medisiner. Dagens Medisin 6.12.2007. www.dagensmedisin.no (27.2.2008).
- 7.
Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 2007; 64: 1475 – 82.
- 8.
European Medicines Agency (EMEA). Scientific discussion. London, 20 March 2005. Product name: LYRICA. Product no: EMEA/H/C/000546/II/0004. www.emea.europa.eu/humandocs/PDFs/EPAR/lyrica/Lyrica%20H-546-II-04-AR.pdf (7.3.2008).
- 9.
Drug Enforcement Administration. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005; 70: 43633 – 5.
- 10.
Oulis P, Konstantakopoulos G, Kouzoupis AV et al. Pregabalin in the discontinuation of long-term benzodiazepines’ use. Hum Psychopharmacol 2008; 23: 337 – 40.
- 11.
Feltner DE, Crockatt JG, Dubovsky SJ et al. High dose pregabalin is effective for the treatment of generalised anxiety disorder. J Clin Psychopharmacol 2003; 23: 240 – 9.